Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Diseases 1Primary Myelofibrosis 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Polycythemia Vera 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Myeloproliferative Disorders 1

Interventions

Fulvestrant 4trastuzumab deruxtecan 2elacestrant 2Vinorelbine 2AZD9833 2toripalimab 1talazoparib 1ribociclib 1pyrotinib 1palbociclib 1olaparib 1exemestane 1eribulin 1disitamab vedotin 1dalpiciclib 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1Radiotherapy 1RAD1901 1Letrozole 1Injections 1Gonadotropin-Releasing Hormone 1Everolimus 1Capecitabine 1Aromatase Inhibitors 1Anastrozole 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Breast Cancer × talazoparib × Clear all
NCT04892693 2025-04-17

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Seoul National University Hospital

Phase 2 Recruiting
70 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡